A
EXAS

Astrantus’s Exact Sciences EXAS Stock Holding History

Astrantus’s Portfolio EXAS Stock Details EXAS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$322K Buy
+4,600
New +$336K 0.54% 106

Other funds holding EXAS

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Astrantus's EXAS Position: Q1 2022 in Review

Astrantus opened a new position in Exact Sciences (EXAS) in Q1 2022: 4,600 shares worth $322K. The stake represents 0.54% of the portfolio and ranks #106 among its holdings.

559 funds tracked by Wall St. Rank hold EXAS as of Q1 2022.

  • Astrantus held 4,600 shares of Exact Sciences worth $322K as of Q1 2022.
  • Exact Sciences was a new Astrantus position in Q1 2022.
  • Exact Sciences made up 0.54% of Astrantus's portfolio in Q1 2022, its #106 holding.
  • 559 funds tracked by Wall St. Rank held Exact Sciences as of Q1 2022.

Based on Astrantus's 13F filing for Q1 2022, filed 11 May 2022.